Cipher Pharmaceuticals Inc.
CPH.TO
TSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 25.11% | 11.49% | 9.92% | 2.36% | -2.16% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.11% | 11.49% | 9.92% | 2.36% | -2.16% |
| Cost of Revenue | 25.58% | 9.34% | 7.85% | 1.93% | 1.55% |
| Gross Profit | 24.99% | 12.01% | 10.40% | 2.46% | -3.00% |
| SG&A Expenses | 68.33% | 18.87% | 25.53% | 19.34% | 13.56% |
| Depreciation & Amortization | 114.59% | -17.67% | -0.34% | 24.06% | 99.85% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.72% | 9.23% | 16.23% | 12.83% | 15.15% |
| Operating Income | -5.92% | 13.87% | 4.16% | -6.77% | -15.10% |
| Income Before Tax | -20.48% | 10.61% | 14.89% | 10.47% | -4.22% |
| Income Tax Expenses | 68.91% | 39.04% | 38.55% | 49.19% | -859.74% |
| Earnings from Continuing Operations | -51.08% | -19.36% | -16.35% | -23.48% | 231.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.08% | -19.36% | -16.35% | -23.48% | 231.89% |
| EBIT | -5.92% | 13.87% | 4.16% | -6.77% | -15.10% |
| EBITDA | 7.35% | 10.05% | 3.73% | -4.28% | -10.40% |
| EPS Basic | -49.02% | -17.23% | -14.70% | -22.50% | 238.29% |
| Normalized Basic EPS | -3.47% | 14.00% | 18.92% | 14.69% | -0.20% |
| EPS Diluted | -49.60% | -17.79% | -14.65% | -22.73% | 242.39% |
| Normalized Diluted EPS | -3.76% | 13.76% | 18.89% | 14.73% | -0.53% |
| Average Basic Shares Outstanding | -3.31% | -3.03% | -1.91% | -1.47% | -1.71% |
| Average Diluted Shares Outstanding | -3.00% | -2.89% | -1.95% | -1.52% | -1.45% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
